Study:
A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders
Rationale:
Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the
growth of cancer cells. The cancer is said to be resistant to chemotherapy. Giving ascorbic
acid may reduce drug resistance and allow the cancer cells to be killed. Thalidomide may
stop the growth of cancer cells by blocking blood flow to the cancer. Giving arsenic
trioxide together with ascorbic acid, dexamethasone, and thalidomide may kill more cancer
cells.
Purpose:
This phase II trial is studying how well giving arsenic trioxide together with
ascorbic acid, dexamethasone, and thalidomide works in treating patients with chronic
idiopathic myelofibrosis or myelodysplastic or myeloproliferative disorders.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases |
Dietary Supplement: ascorbic acid
Drug: arsenic trioxide
Drug: dexamethasone
Drug: thalidomide |
Phase 2 |
Verified by
Case Comprehensive Cancer Center
September, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00274820
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Mikkael A. Sekeres, MD, MS., Study Chair